Goodlad John R, Krajewski Andrew S, Batstone Paul J, McKay Pam, White Jo M, Benton E Claire, Kavanagh Gina M, Lucraft Helen H
Department of Pathology, Raigmore Hospital, Inverness, Scotland, United Kingdom.
Am J Surg Pathol. 2003 Dec;27(12):1538-45. doi: 10.1097/00000478-200312000-00006.
Classification and subdivision of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) are a matter of ongoing debate. In this study we assessed the morphologic, immunophenotypic, and clinical features of 30 cases of PCDLBCL identified during a review of all primary cutaneous B-cell lymphomas in the Scotland and Newcastle Lymphoma Group database. We also determined the number of cases harboring t(14;18) using a polymerase chain reaction and primers to the major breakpoint cluster region. The effect on prognosis of a variety of clinical and pathologic factors was assessed for the group of 30 PCDLBCL and the 5-year disease-specific survival (DSS) of this cohort compared with that of 195 cases of stage I diffuse large B-cell lymphoma arising primarily in lymph nodes, also identified from within the Scotland and Newcastle Lymphoma Group database. Location on the leg was the only independent prognostic factor for determining outcome in PCDLBCL (67% 5-year DSS compared with 100% for the upper body; P = 0.0047). The presence of multiple lesions, involvement of more than one body site, and expression or not of CD10, bcl-2, bcl-6, and CD10 and bcl-6, had no effect on survival. Compared with cases arising above the waist, those on the leg were more often female, were of an older age, and had a significantly higher incidence of bcl-2 expression (P = 0.002) as well as the aforementioned poorer prognosis. They also showed more frequent co-expression of CD10 and bcl-6, supporting a follicle center cell origin for some, but this difference was not statistically significant. Although there was no significant difference in the 5-year DSS between the group of PCDLBCL and the cases of stage I nodal diffuse large B-cell lymphoma (88% 5-year DSS vs. 78%; P = 0.06), the latter were generally treated with more aggressive therapy. Moreover, a significant difference in 5-year DSS was seen when the nodal DLBCLs were compared with PCDLBCLs arising above the waist (78% vs. 100% respectively; P = 0.0135). These results support the current EORTC approach of subdividing PCLBCL on the basis of site to produce prognostically relevant groupings.
原发性皮肤弥漫性大B细胞淋巴瘤(PCDLBCL)的分类和细分一直存在争议。在本研究中,我们评估了苏格兰和纽卡斯尔淋巴瘤组数据库中所有原发性皮肤B细胞淋巴瘤回顾期间确定的30例PCDLBCL的形态学、免疫表型和临床特征。我们还使用聚合酶链反应和针对主要断裂点簇区域的引物确定了携带t(14;18)的病例数。评估了30例PCDLBCL组中各种临床和病理因素对预后的影响,并将该队列的5年疾病特异性生存率(DSS)与同样从苏格兰和纽卡斯尔淋巴瘤组数据库中确定的195例主要发生在淋巴结的I期弥漫性大B细胞淋巴瘤的5年疾病特异性生存率进行了比较。腿部位置是决定PCDLBCL预后的唯一独立预后因素(5年DSS为67%,而上半身则为100%;P = 0.0047)。多发病变的存在、多个身体部位的受累以及CD10、bcl-2、bcl-6以及CD10和bcl-6的表达与否对生存率均无影响。与腰部以上发生的病例相比,腿部病例女性更多、年龄更大,bcl-2表达的发生率显著更高(P = 0.002),且预后更差。它们还显示出更频繁的CD10和bcl-6共表达,支持部分病例起源于滤泡中心细胞,但这种差异无统计学意义。尽管PCDLBCL组与I期淋巴结弥漫性大B细胞淋巴瘤组的5年DSS无显著差异(5年DSS分别为88%和78%;P = 0.06),但后者通常接受更积极的治疗。此外,当将淋巴结弥漫性大B细胞淋巴瘤与腰部以上发生的PCDLBCL进行比较时,5年DSS存在显著差异(分别为78%和100%;P = 0.0135)。这些结果支持了目前欧洲癌症研究与治疗组织(EORTC)根据部位对原发性皮肤大B细胞淋巴瘤进行细分以产生预后相关分组的方法。